Green Cross Cell Applies for Phase 3 Clinical Trial Protocol for Pancreatic Cancer

[Asia Economy Reporter Oh Ju-yeon] Green Cross Cell announced on the 6th that it has applied for a Phase 3 clinical trial plan to evaluate the efficacy and safety of ImmunCell-LC injection combined with gemcitabine as an adjuvant therapy compared to gemcitabine monotherapy for pancreatic cancer treatment. The company explained, "Pancreatic cancer has a very poor prognosis with a 5-year relative survival rate of 12.2%, which is lower than other cancer types," and added, "There is no clearly proven anticancer treatment effective after gemcitabine." They further stated, "If efficacy and safety for pancreatic cancer are demonstrated through this clinical trial, it will be possible to secure additional indications for gemcitabine combination therapy," and "It is expected to expand the market and increase sales by adding pancreatic cancer indications to the currently held liver cancer indications."

This content was produced with the assistance of AI translation services.